Intrinsiqq
Rapport Therapeutics Inc. logo

Rapport Therapeutics Inc. Insider Trading

RAPP

Compare
Cluster buy

7 insiders bought $22M of their own stock in 8 days.

Open-market purchases by executives and directors between Oct 21 and Oct 28. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market
+$9.68M
7 buys · 28 sales
Under a 10b5-1 plan
97%
of the value sold
Insiders who bought / sold
7 / 4
executives and directors
Last open-market buy
Oct 2026
Oct 28, 2026

Get an email when RAPP's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 28
    James Healy
    Director · bought 969,480 at avg $21.00
    $20.4M
    51% of stake
  • Oct 23
    Ramiro Sanchez
    Director · bought 3,600 at $27.35
    98K
    New position
  • Oct 22
    Paul M Silva
    Director · bought 3,680 at $27.08
    100K
    New position
  • Oct 22
    Wendy B. Young
    Director · bought 3,789 at $26.39
    100K
    40% of stake
  • Oct 22
    Steven M Paul
    Director · bought 35,714 at $27.28
    974K
    6.9% of stake
  • Oct 22
    John Maraganore
    Director · bought 9,411 at avg $26.45
    249K
    New position
  • Oct 2110b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 2,210 at $29.16
    64K
    0.4% of stake
  • Oct 21
    Troy A. Ignelzi
    Chief Financial Officer · bought 5,500 at $26.10
    144K
    55% of stake
  • Oct 6 – 710b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 4,522 at avg $31.68
    143K
    0.8% of stake
  • Sep 3010b5-1 plan
    Cheryl Gault
    Chief Operating Officer · sold 10,000 at avg $33.19
    332K
    6.7% of stake
  • Sep 2310b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 2,210 at avg $39.17
    87K
    0.4% of stake
  • Sep 810b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 8,210 at avg $45.62
    375K
    1.4% of stake
  • Aug 2510b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 18,921 at $49.57
    938K
    3.2% of stake
  • Aug 24 – 2510b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 50,160 at avg $50.47
    $2.53M
    20% of stake
  • Aug 1910b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 404 at $49.90
    20K
    0.2% of stake
  • Aug 10 – 1110b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 51,499 at avg $47.24
    $2.43M
    8.0% of stake
  • Jul 2710b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 2,210 at avg $42.11
    93K
    0.3% of stake
  • Jul 1410b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 8,210 at avg $40.00
    328K
    1.3% of stake
  • Jun 3010b5-1 plan
    Cheryl Gault
    Chief Operating Officer · sold 10,000 at avg $41.58
    416K
    6.3% of stake
  • Jun 2910b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 8,220 at avg $39.83
    327K
    1.2% of stake
  • May 2610b5-1 plan
    Third Rock Ventures V, L.p.
    Large holder · sold 18,572 at $40.05
    744K
    0.3% of stake
  • May 1110b5-1 plan
    Third Rock Ventures V, L.p.
    Large holder · sold 133,618 at $40.24
    $5.38M
    1.8% of stake
  • May 7 – 810b5-1 plan
    Third Rock Ventures VI, L.p.
    Large holder · sold 276,513 at avg $40.12
    $11.1M
    3.6% of stake
  • Apr 1710b5-1 plan
    Third Rock Ventures VI, L.p.
    Large holder · sold 426,005 at $40.32
    $17.2M
    5.3% of stake
  • Apr 1710b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 20,225 at $39.99
    809K
    7.6% of stake
  • Apr 10 – 1410b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 19,865 at avg $35.03
    696K
    6.9% of stake
  • Apr 810b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 360 at $34.90
    13K
    0.1% of stake
  • Mar 3010b5-1 plan
    Cheryl Gault
    Chief Operating Officer · sold 10,000 at avg $28.18
    282K
    5.9% of stake
  • Mar 2510b5-1 plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 10,115 at $29.99
    303K
    3.4% of stake
  • Mar 5No plan
    Cheryl Gault
    Chief Operating Officer · sold 2,014 at $28.93
    58K
    1.2% of stake
  • Feb 1810b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 10,916 at avg $29.35
    320K
    1.6% of stake
  • Feb 1710b5-1 plan
    David Bredt
    Chief Scientific Officer · sold 8,500 at avg $29.02
    247K
    2.1% of stake
  • Jan 2010b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 10,916 at avg $26.12
    285K
    1.6% of stake
  • Jan 1510b5-1 plan
    David Bredt
    Chief Scientific Officer · sold 8,500 at avg $26.84
    228K
    2.1% of stake
  • Dec 31, 2025No plan
    David Bredt
    Chief Scientific Officer · sold 6,567 at $30.05
    197K
    1.6% of stake
  • Dec 31, 2025No plan
    Krishnaswamy Yeleswaram
    Chief Development Officer · sold 2,840 at $30.05
    85K
    0.9% of stake
  • Dec 17, 202510b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 10,916 at avg $29.64
    324K
    1.6% of stake
  • Dec 15, 202510b5-1 plan
    David Bredt
    Chief Scientific Officer · sold 8,500 at avg $30.02
    255K
    2.1% of stake
  • Nov 26, 202510b5-1 plan
    Cheryl Gault
    Chief Operating Officer · sold 5,000 at $30.10
    151K
    2.8% of stake
  • Nov 17, 202510b5-1 plan
    Abraham Ceesay
    Chief Executive Officer · sold 10,916 at avg $25.20
    275K
    1.6% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RAPP, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RAPP

CompareIntrinsic value
NAMSNewAmsterdam Pharma Co. N.V.
$18.41-5.64%10
MCRBSeres Therapeutics, Inc.
$1.24-6.77%0
EOLSEvolus Inc.
$6.52-6.86%30
ARQTArcutis Biotherapeutics Inc.
$26.36-2.98%65
URGNUrogen Pharma Ltd.
$27.65-12.86%30
GERNGeron Corporation
$0.87-4.32%10
HRMYHarmony Biosciences Holdings, Inc.
$32.59-1.18%80
DNTHDianthus Therapeutics Inc.
$84.55-0.33%10

Held by ETFs

RAPP is in 32 US ETFs. The largest of them, with RAPP's weight in each:

Spot a number that looks wrong? Check it in RAPP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing RAPP

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.